US 12,383,578 B2
Carbazate-activated polyvinyl alcohol (PVAC) as a polymer-based antitumoral agent
David Berglund, New York, NY (US); Erik Berglund, New York, NY (US); Felix Sellberg, Uppsala (SE); and Robin Fröbom, Stockholm (SE)
Assigned to CreMed AB, Stockholm (SE)
Appl. No. 17/776,643
Filed by CREMED AB (PUBL), Stockholm (SE)
PCT Filed Nov. 18, 2020, PCT No. PCT/SE2020/051105
§ 371(c)(1), (2) Date May 13, 2022,
PCT Pub. No. WO2021/101433, PCT Pub. Date May 27, 2021.
Claims priority of application No. 1930380-9 (SE), filed on Nov. 21, 2019.
Prior Publication US 2022/0401470 A1, Dec. 22, 2022
Int. Cl. A61K 31/785 (2006.01); A61K 45/06 (2006.01); A61P 17/00 (2006.01); A61P 35/00 (2006.01); C08F 116/06 (2006.01)
CPC A61K 31/785 (2013.01) [A61K 45/06 (2013.01); A61P 17/00 (2018.01); A61P 35/00 (2018.01); C08F 116/06 (2013.01)] 7 Claims
 
1. A method for alleviating and/or treating cancer in a subject comprising administering a therapeutically effective amount of a polymer comprising a carbazate-modified polyvinyl alcohol (PVAC) of Formula I,

OG Complex Work Unit Chemistry
wherein,
unmodified repeat units of PVA are denoted with n and carbazate groups conjugated to repeat units are denoted by m,
to a subject in need of such treatment.